Ftse Mib
33.766,29
-0,06%
DAX
19.884,75
-0,57%
S&P 500
5.930,85
1,09%
NASDAQ
19.572,60
1,03%
Bitcoin
95.614,82
-1,63%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Spyre Therapeutics Inc (SYRE) Spyre Therapeutics Inc (SYRE) Notizie

Spyre Therapeutics Inc

SYRE
23,86
0,73 (3,16%)
21 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/12/202414:00PRNUSSpyre Therapeutics Added to the Nasdaq Biotechnology Index
02/12/202423:03PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
02/12/202414:00PRNUSSpyre Therapeutics Announces First Participants Dosed in..
25/11/202423:11PRNUSSpyre Therapeutics to Participate in the 7th Annual Evercore..
19/11/202423:15EDGAR2Form 8-K - Current report
19/11/202422:38EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/11/202403:18PRNUSSpyre Therapeutics Announces Pricing of $200 Million Public..
18/11/202423:10EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/11/202422:14PRNUSSpyre Therapeutics Announces Proposed Public Offering of its..
18/11/202422:09EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
18/11/202422:06EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
18/11/202422:05EDGAR2Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]:..
18/11/202422:03EDGAR2Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
18/11/202422:01EDGAR2Form 8-K - Current report
14/11/202423:50EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202422:05EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
14/11/202415:44EDGAR2Form SC 13G/A - Statement of Beneficial Ownership by Certain..
12/11/202413:30PRNUSSpyre Therapeutics Announces Positive Interim Results from..
11/11/202422:05PRNUSSpyre Therapeutics to Host Conference Call and Webcast to..
08/11/202422:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/11/202422:14EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/11/202422:06EDGAR2Form 8-K - Current report
07/11/202422:05PRNUSSpyre Therapeutics Reports Third Quarter 2024 Financial..
07/11/202422:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
01/11/202421:44PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
30/10/202421:05PRNUSSpyre Therapeutics to Participate in Upcoming November..
28/10/202421:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/10/202422:28EDGAR2Form 144 - Report of proposed sale of securities
23/10/202420:10EDGAR2Form SC 13G - Statement of Beneficial Ownership by Certain..
15/10/202412:10EDGAR2Form 8-K - Current report
14/10/202414:00PRNUSSpyre Therapeutics Announces Expected Acceleration of SPY003..
04/10/202423:00PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
03/10/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
02/10/202400:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202400:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
01/10/202414:00PRNUSSpyre Therapeutics Appoints Dr. Sheldon Sloan as Chief..
20/9/202422:05EDGAR2Form S-3 - Registration statement under Securities Act of..
10/9/202422:47PRNUSSpyre Therapeutics to Participate in Upcoming Investor..
06/9/202422:06EDGAR2Form S-3 - Registration statement under Securities Act of..
05/9/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/8/202422:17EDGAR2Form 8-K - Current report
07/8/202422:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/8/202422:05PRNUSSpyre Therapeutics Reports Second Quarter 2024 Financial..
18/7/202414:00GLOBENewAmsterdam Pharma Announces Appointments of Mark C...
18/6/202413:30PRNUSSpyre Therapeutics Announces First Participants Dosed in..
03/6/202423:23PRNUSSpyre Therapeutics Announces Grants of Inducement Awards
30/5/202422:33EDGAR2Form 8-K - Current report
29/5/202414:30PRNUSSpyre Therapeutics to Participate in the Jefferies Global..
16/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 22,755 Min: 22,62 Max: 24,88
Chiusura: 23,13

La tua Cronologia

NASDAQ
SYRE
Spyre Therapeutics
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network